BlackRock’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $305K | Sell |
508,000
-58,905
| -10% | -$35.4K | ﹤0.01% | 4498 |
|
2025
Q1 | $153K | Sell |
566,905
-26,421
| -4% | -$7.13K | ﹤0.01% | 4610 |
|
2024
Q4 | $309K | Buy |
593,326
+25,446
| +4% | +$13.2K | ﹤0.01% | 4481 |
|
2024
Q3 | $1.84M | Sell |
567,880
-5,434
| -0.9% | -$17.6K | ﹤0.01% | 3973 |
|
2024
Q2 | $1.72M | Sell |
573,314
-4,874
| -0.8% | -$14.6K | ﹤0.01% | 3957 |
|
2024
Q1 | $2.69M | Buy |
578,188
+5,445
| +1% | +$25.3K | ﹤0.01% | 3838 |
|
2023
Q4 | $2.37M | Sell |
572,743
-1,364
| -0.2% | -$5.65K | ﹤0.01% | 3904 |
|
2023
Q3 | $1.72M | Sell |
574,107
-31,147
| -5% | -$93.4K | ﹤0.01% | 3994 |
|
2023
Q2 | $1.49M | Sell |
605,254
-1,233,163
| -67% | -$3.03M | ﹤0.01% | 4088 |
|
2023
Q1 | $4.15M | Sell |
1,838,417
-24,725
| -1% | -$55.9K | ﹤0.01% | 3632 |
|
2022
Q4 | $6.5M | Sell |
1,863,142
-290,186
| -13% | -$1.01M | ﹤0.01% | 3533 |
|
2022
Q3 | $79.7M | Buy |
2,153,328
+417
| +0% | +$15.4K | ﹤0.01% | 2095 |
|
2022
Q2 | $40.9M | Buy |
2,152,911
+200,103
| +10% | +$3.8M | ﹤0.01% | 2591 |
|
2022
Q1 | $52.7M | Buy |
1,952,808
+567,573
| +41% | +$15.3M | ﹤0.01% | 2514 |
|
2021
Q4 | $31.2M | Buy |
1,385,235
+174,994
| +14% | +$3.94M | ﹤0.01% | 2946 |
|
2021
Q3 | $31.7M | Sell |
1,210,241
-259,866
| -18% | -$6.81M | ﹤0.01% | 2925 |
|
2021
Q2 | $47.1M | Sell |
1,470,107
-18,068
| -1% | -$578K | ﹤0.01% | 2701 |
|
2021
Q1 | $52.4M | Sell |
1,488,175
-4,844
| -0.3% | -$171K | ﹤0.01% | 2545 |
|
2020
Q4 | $47.9M | Buy |
1,493,019
+280,318
| +23% | +$8.99M | ﹤0.01% | 2455 |
|
2020
Q3 | $45.6M | Sell |
1,212,701
-4,064
| -0.3% | -$153K | ﹤0.01% | 2308 |
|
2020
Q2 | $54.4M | Buy |
1,216,765
+738,752
| +155% | +$33.1M | ﹤0.01% | 2176 |
|
2020
Q1 | $16.3M | Buy |
478,013
+334,900
| +234% | +$11.4M | ﹤0.01% | 2672 |
|
2019
Q4 | $5.58M | Buy |
+143,113
| New | +$5.58M | ﹤0.01% | 3421 |
|